Magnolia Wealth Management’s AbbVie ABBV Stock Holding History

Magnolia Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-244	Closed	-$53.1K	–	18
2026 Q1	$53.1K	Buy	+244	New	+$54.1K	0.03%	47

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Magnolia Wealth Management's ABBV Position: Q2 2026 in Review

Magnolia Wealth Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 244 shares — an estimated $53.1K sold.

Magnolia Wealth Management first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $53.1K in Q1 2026. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Magnolia Wealth Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Magnolia Wealth Management sold 244 AbbVie shares in Q2 2026, an estimated $53.1K.
Magnolia Wealth Management first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
Magnolia Wealth Management's AbbVie position peaked at $53.1K in Q1 2026.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Magnolia Wealth Management's 13F filing for Q2 2026, filed 14 Jul 2026.